About us
A contract manufacturer built around a research group
Most CDMOs add R&D to a factory. We did it the other way round — and that ordering explains almost everything about how we work.
- Growth since 2013
- 50×Growth since 2013₹2 Cr to ₹100 Cr revenue
- Formulations developed
- 350+Formulations developedAcross ten therapeutic areas
- PCT patents filed
- 9+PCT patents filedProprietary actives, protected
- Countries served
- 25+Countries servedRegulatory dossiers included
Origin
How we got here
Makin Laboratories was established in Indore in 1987. In 2013 Yash Sharma acquired it — a ₹2 crore business working out of 1,600 square feet — and put a straightforward proposition to it: manufacture herbal and nutraceutical products to the standards pharmaceutical companies take for granted. That meant validated processes, controlled environments and documentation that holds up under audit, applied to a category where none of it was assumed.
The R&D group followed, because customers kept arriving with formulations that could not work as written. Actives that would not stay stable through shelf life. Botanicals with strong in vitro data and no measurable absorption. Answering those briefs properly required designing formulations rather than filling them, and that capability became the business.
Today the same campus holds the laboratory, the patent practice and a WHO-GMP plant. Revenue has grown fiftyfold, 350+ formulations have been developed, and nine PCT applications protect molecules of our own. The proposition has not changed — only the depth behind it.
Timeline
The route so far
1987
Established in Indore
Makin Laboratories begins as a traditional Ayurvedic manufacturing unit, and runs as one for twenty-six years.
2013
Acquired and redirected
Yash Sharma takes over a ₹2 crore business in 1,600 square feet and rebuilds it around pharmaceutical discipline.
2016
Certification and export
WHO-GMP and the ISO family are secured, opening regulated export markets across Africa and Asia.
2019
In-house R&D formalised
A dedicated formulation laboratory is established to take on briefs other manufacturers decline.
2023
Patents and preclinical work
PCT applications are filed on proprietary actives; preclinical studies begin across the portfolio.
2026
Peer-reviewed publication
Preclinical evidence for Ostizeel™ is published in Inflammopharmacology, and international expansion begins.
Leadership
The people behind it
The same two people have directed the company since 2013.
Yash Sharma
Managing Director
Began in pharmaceutical sales, learning the industry from the territory upward. Acquired Makin in 2013 and rebuilt it around formulation science rather than filling capacity. Turnover has grown fiftyfold since.
Radhika Sharma
Chairperson
Joined from outside the pharmaceutical industry during the company's most demanding years, carrying both the operational load and the argument for what it should become. As Chairperson she sets governance and long-term direction.
Vision
To set the global standard for nutraceutical formulation — where ingredient science, preclinical validation and pharmaceutical-grade manufacturing sit in the same building.
Mission
To be the manufacturing partner nutraceutical, herbal and cosmeceutical brands trust worldwide: formulation expertise, certified quality and end-to-end supply, answerable for results rather than promises.
Principles
How we work
- We say no
- If a formulation cannot be made to do what a claim requires, we say so before the contract, not after the trial. An honest no costs us one project and saves the customer a launch.
- Mechanism before marketing
- The pharmacology decides the delivery system, the excipient matrix and the dose. Not the other way round, and not what happens to compress easily.
- Documentation is part of the product
- A batch that cannot be defended in an audit is not finished. Dossiers, stability data and certificates ship with the goods.
Bring us the formulation that has not worked yet.
Tell us the mechanism you are targeting and the market you are selling into. We will tell you honestly whether we can engineer it, and what it will take.